Impact Factor
2.54
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.26
75 total citations
h5-index
17
h5 depth signal
Cited share
53.2%
33 of 62
Total citations
75
Citation footprint
Metric signal
1.57
External metric anchor
Self-citation
0.0%
0 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Italy
64
China
62
Japan
44
United States
25
Turkey
12
Citing Fields of Research
Oncology
82
Antibiotic & Antibacterial Agents
53
Hematology
44
Cancer Drugs
42
Lung Cancer
34
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,624
Articles tracked across the journal lifetime
Indexed publication set
62
33 cited publications
Last 12 months
9
1.1 publications/month
Open access share
22.2%
2 OA publications in the last year
Leading citing country
Italy
64 citing publications
Leading citing field
Oncology
82 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v13n1, 1968-
v13n1, 1968-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Cancer Drugs
Antibiotic & Antibacterial Agents
Urology
Immunology
Hematology
Issuing & Sponsoring Bodies
Contributor
International Society of Chemotherapy
Broad Categories
Drug Therapy
Lymphomas
Antibiotic & Antibacterial Agents
Lung Cancer
Digestive Disorders
Hematology
Urology
MeSH Descriptors
Drug Therapy
Pharmacology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1159/che/aceag001
Open DOI
Cerebrospinal fluid penetration of new antibiotics in the treatment of central nervous system infections
Background: Multidrug-resistant (MDR) bacterial infections present significant challenges to the management of central nervous system (CNS) infections, particularly in neurosurgical patients and those with cerebrospinal fluid (CSF) diver...
02
DOI 10.1159/000553329
Open DOI
Therapeutic Drug Monitoring of Linezolid in Real-World Clinical Practice: Determinants of Exposure, Dose Optimization, and Hematological Toxicity
Introduction: Linezolid exhibits significant pharmacokinetic variability in hospitalized patients, which may lead to suboptimal exposure or toxicity. Therapeutic drug monitoring (TDM) has been proposed to optimize treatment, although rea...
03
DOI 10.1159/000553142
Open DOI
Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy
Background Monoclonal antibodies (mAbs) and their derivatives represent a central pillar of contemporary oncology, with expanding complexity in molecular design and clinical application. Beyond unconjugated mAbs, bispecific, trispecific ...
04
DOI 10.1159/000552926
Open DOI
Pseudoprogression of a head and neck cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy: a case report and review of the literature
Pseudoprogression during immunotherapy (IO) - defined as clinical documentation of tumor growth or new lesions during treatment with immune checkpoint inhibitors, followed by disease regression – has been reported in ≤10% of cases. Its i...
05
DOI 10.1159/000552622
Open DOI
Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A case series
Introduction: The introduction of enfortumab vedotin plus pembrolizumab (EVP) has caused a paradigm shift in the first-line treatment strategies for metastatic urothelial carcinoma (mUC). However, no standard subsequent therapy has been ...
06
DOI 10.1159/000551380
Open DOI
Efficacy and Safety Study of Different Doses of Linezolid in Combination with Bedaquiline in the Treatment of Drug-Resistant Pulmonary Tuberculosis
Introduction: Drug-resistant tuberculosis presents a major global health challenge due to limited therapeutic options and significant toxicity of traditional regimens. Linezolid, a core Group A drug per WHO guidelines, demonstrates high ...
07
DOI 10.1159/000550822
Open DOI
Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?
Background Critically ill patients exhibit acute physiological changes leading to marked antibiotic exposure variability and an increased probability of either subtherapeutic or potentially toxic exposures. Beta-lactam antibiotics are of...
08
DOI 10.1159/000549719
Open DOI
Expression of Concern
09
DOI 10.1159/000550093
Open DOI
Drug-Drug Interaction between Toosendanin and Tamoxifen and Its Potential Mechanism
Introduction: Toosendanin has shown anticancer activity in various malignancies, including gynecological cancers. As tamoxifen is a cornerstone therapy for breast and ovarian cancers, this study investigated how toosendanin alters its ph...
10
DOI 10.1159/000549024
Open DOI
Acknowledgement to Reviewers
Bibliographical & Catalog Notes
Supplements accompany some volumes.
Also issued online.
Official organ of the International Society of Chemotherapy.
Vol. 38, no. 1 (1992)19921001 Notice published Printed on acid-free paper